一、人员组成
教授：徐戎
副教授：刘慧
二、研究方向
肿瘤药理学；纳米医学；临床药理学；新药研究与评价
三、主要研究工作
徐戎教授课题组的主要研究工作围绕新型纳米药物构建、肿瘤药效学评价、肿瘤相关信号通路开展相关研究。近年来课题组应用纳米医学、细胞生物学、分子生物学等现代实验技术，构建了可有效携载化疗药物、核酸药物的抗肿瘤新型纳米载体，并揭示了中药活性成分的抗肿瘤作用及作用机制。这些工作分别以研究文章的形式发表在国际著名学术刊物Nat Biotechnol、ACS Nano、Small、Nanoscale、J Exp Clin Cancer Res、Int J Nanomedicine上。研究工作得到了国家自然科学基金、湖北省自然科学基金杰出青年基金、湖北省卫生和计划生育委员会青年人才项目、武汉市科技计划等基金的支持。
四、代表性科研项目
国家自然科学基金面上及青年基金项目
湖北省自然科学基金杰青项目
湖北省卫生和计划生育委员会青年人才项目
武汉市科技计划项目
华中科技大学院系自主创新研究基金重点项目
五、代表性论文
1.Wu Z, Zhu L, Mai J, Shen H,Xu R. Rad51 Silencing with siRNA delivered by porous silicon-based microparticle enhances the anti-cancer effect of doxorubicin in triple-negative breast cancer. J Biomed Nanotechnol. 2021 Dec1;17(12):2351-2363.
2.He W, Qin M, Cai Y, Gao X, Cao S, Wang Z, Chen H*,Xu R*. Downregulation of HOXC6 by miR-27a ameliorates gefitinib resistance in non-small cell lung cancer.Am J Cancer Res. 2021 Sep 15;11(9):4329-4346.
3.Ming JX, Wang ZC, Huang Y, Ohishi H, Wu RJ, Shao Y, Wang H, Qin MY, Wu ZL, Li YY, Chang Zhou S, Chen H, Liu H,Xu R. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. J Ethnopharmacol. 2021 Jan 30;265:113302.
4.Wu ZL, Zhao J,Xu R. Recent advances in oral nano-antibiotics for bacterialinfection therapy.Int J Nanomedicine. 2020 Dec 1;15:9587-9610.
5.Gao X, Cai Y, Wang Z, He W, Cao S,Xu R, Chen H. Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective. J Transl Med. 2019 Sep 11;17(1):308.
6.Cao S, Wang Z, Gao X, He W, Cai Y, Chen H*,Xu R*. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res. 2018 Sep 6;37(1):220.
7.Tang Y#, Li Y#,Xu R#, Li S, Hu H, Xiao C, Wu H, Zhu L, Ming J, Chu Z, Xu H, Yang X, Li Z. Self-assembly of folic acid dextran conjugates for cancer chemotherapy. Nanoscale. 2018 Sep 20;10(36):17265-17274.
8.Mai J, Li X, Zhang G, Huang Y,Xu R, Shen Q, Lokesh GL, Thiviyanathan V, Chen L, Liu H, Zu Y, Ma X, Volk DE, Gorenstein DG, Ferrari M, Shen H. DNA thioaptamer with homing specificity to lymphoma bone marrow involvement.Mol Pharm. 2018 May 7;15(5):1814-1825.
9.Liu H, Mai J, Shen J, Wolfram J, Li Z, Zhang G,Xu R, Li Y, Mu C, Zu Y, Li X, Lokesh GL, Thiviyanathan V, Volk DE, Gorenstein DG, Ferrari M, Hu Z, Shen H. A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells.Theranostics. 2018 Jan 1;8(1):31-44.
10.Mei C, Zhou S, Zhu L, Ming J, Zeng F,Xu R. Antitumor effects of laminaria extract fucoxanthin on lung cancer. Mar Drugs. 2017 Feb 15;15(2). pii: E39.
11.Wang Z, Kerketta R, Chuang YL, Dogra P, Butner JD, Brocato TA, Day A,Xu R, Shen H, Simbawa E, Al-Fhaid AS, Mahmoud SR, Curley SA, Ferrari M, Koay EJ, Cristini V. Theory and experimental validation of a spatio-temporal model of chemotherapy transport to enhance tumor cell kill. PLoS Comput Biol. 2016 Jun 10;12(6):e1004969.
12.Xu R#, Zhang G#, Mai J#, Deng X#, Segura-Ibarra V, Wu S, Shen J, Liu H, Hu Z, Chen L, Huang Y, Koay E, Huang Y, Liu J, Ensor JE, Blanco E, Liu X, Ferrari M, Shen H. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat Biotechnol. 2016 Apr;34(4):414-8.
13.Zhu Y, He W, Gao X, Li B, Mei C,Xu R, Chen H. Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. Sci Rep. 2015 Dec 4;5:17730.
14.Xia X, Mai J,Xu R, Perez JE, Guevara ML, Shen Q, Mu C, Tung HY, Corry DB, Evans SE, Liu X, Ferrari M, Zhang Z, Li XC, Wang RF, Shen H. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. Cell Rep. 2015 May 12;11(6):957-66.
15.Gizzatov A, Stigliano C, Ananta JS, Sethi R,Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P. Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett. 2014 Sep 28;352(1):97-101.
16.Mai J, Huang Y, Mu C, Zhang G,Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan V, Gorenstein DG, Liu X, Ferrari M, Shen H. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. J Control Release. 2014 Aug 10;187:22-9.
17.Shen J#,Xu R#, Mai J#, Kim HC, Guo X, Qin G, Yang Y, Wolfram J, Mu C, Xia X, Gu J, Liu X, Mao ZW, Ferrari M, Shen H. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano. 2013 Nov 26;7(11):9867-80.
18.Shen H, Rodriguez-Aguayo C,Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013 Apr 1;19(7):1806-15.
19.Zhang M,Xu R, Xia X, Yang Y, Gu J, Qin G, Liu X, Ferrari M, Shen H. Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. Biomaterials. 2014 Jan;35(1):423-31.
20.Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small. 2013 May 27;9(9-10):1799-808.
(Updated in June, 2022)
